View in EDS HTML Full Text PDF Full Text

Healthcare resource utilization of maribavir versus investigator‐assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial

Saved in:
Bibliographic Details
Title: Healthcare resource utilization of maribavir versus investigator‐assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial
Authors: Hirji, Ishan1 (AUTHOR) ishan.hirji@takeda.com, Cocks, Kim2 (AUTHOR), Moreno‐Koehler, Alejandro3 (AUTHOR), Sundberg, Aimee4 (AUTHOR)
Source: Transplant Infectious Disease. Jun2023, Vol. 25 Issue 3, p1-6. 6p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13982273
DOI:10.1111/tid.14064